Cadila Healthcare’s manufacturing facility located in Baddi, has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), stating that the classification of the facility is in ‘No Action Indicated (NAI)'. The USFDA had conducted inspection at the company’s formulations manufacturing facility at Baddi in Himachal Pradesh from July 15-19, 2019.